Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS)
- PMID: 15486872
- DOI: 10.1053/j.ajkd.2004.08.009
Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS)
Abstract
Background: Mineral metabolism has emerged as an important predictor of morbidity and mortality in dialysis patients, independent of bone and muscle concerns. Several expert panels have issued management guidelines for mineral metabolism.
Methods: The state of mineral metabolism (serum parathyroid hormone [PTH], phosphorus, calcium, and calcium-phosphorus product) was described for representative samples of patients and facilities from 7 countries (France, Germany, Italy, Japan, Spain, United Kingdom, and United States) participating in the Dialysis Outcomes and Practice Patterns Study (DOPPS I, 1996-2001; DOPPS II, 2002-2004).
Results: A relatively modest percentage of patients fell within the guideline range for PTH (21.4% in DOPPS I, 26.2% in DOPPS II), serum phosphorus (40.8%, 44.4%), albumin-corrected serum calcium (40.5%, 42.5%), and calcium-phosphorus product (56.6%, 61.4%). Results were not dramatically different across countries. The majority of patients not within guideline ranges had high serum levels of phosphorus (51.6% in DOPPS I, 46.7% in DOPPS II), calcium (50.1%, 48.6%), and calcium-phosphorus product (43.4%, 38.6%) and low (<150 pg/mL) concentrations of PTH (52.9%, 47.5%). It was rare for patients to fall within recommended ranges for all indicators of mineral metabolism; 23% to 28% fell within guideline for at least 3 measures and only 4.6% to 5.5% of patients were within range for all 4. The risks of all-cause and cardiovascular mortality were directly and independently associated with each of the 4 indicators.
Conclusion: The DOPPS provides a useful comparison benchmark for the state of mineral metabolism management of patients with kidney disease; it also affirms the association between mineral metabolism and important patient outcomes.
Similar articles
-
Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS).Am J Kidney Dis. 2008 Sep;52(3):519-30. doi: 10.1053/j.ajkd.2008.03.020. Epub 2008 Jun 2. Am J Kidney Dis. 2008. PMID: 18514987
-
Mineral bone disorder and its management among hemodialysis patients in the Gulf Cooperation Council: Initial findings from the dialysis outcomes and practice patterns study (2012-2015).Saudi J Kidney Dis Transpl. 2016 Nov;27(6 Suppl 1):62-80. doi: 10.4103/1319-2442.194902. Saudi J Kidney Dis Transpl. 2016. PMID: 27991480
-
Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study.Kidney Int. 2005 Mar;67(3):1179-87. doi: 10.1111/j.1523-1755.2005.00185.x. Kidney Int. 2005. PMID: 15698460
-
Mineral metabolism and renal bone disease: effects of CAPD versus hemodialysis.Kidney Int Suppl. 1993 Feb;40:S92-100. Kidney Int Suppl. 1993. PMID: 8445845 Review. No abstract available.
-
Selected lessons learned from the Dialysis Outcomes and Practice Patterns Study (DOPPS).Contrib Nephrol. 2005;149:58-68. doi: 10.1159/000085458. Contrib Nephrol. 2005. PMID: 15876829 Review.
Cited by
-
Lanthanum carbonate for the treatment of hyperphosphatemia in CKD 5D: multicenter, double blind, randomized, controlled trial in mainland China.BMC Nephrol. 2013 Feb 4;14:29. doi: 10.1186/1471-2369-14-29. BMC Nephrol. 2013. PMID: 23379590 Free PMC article. Clinical Trial.
-
Role of residual renal function in phosphate control and anemia management in chronic hemodialysis patients.Clin J Am Soc Nephrol. 2011 Feb;6(2):281-9. doi: 10.2215/CJN.04480510. Epub 2010 Oct 28. Clin J Am Soc Nephrol. 2011. PMID: 21030579 Free PMC article. Clinical Trial.
-
Bone health and vascular calcification relationships in chronic kidney disease.Int Urol Nephrol. 2007;39(4):1209-16. doi: 10.1007/s11255-007-9276-9. Epub 2007 Sep 26. Int Urol Nephrol. 2007. PMID: 17899431 Review.
-
Use of percutaneous ethanol injection therapy for recurrent secondary hyperparathyroidism after subtotal parathyroidectomy.Int J Nephrol. 2011;2011:246734. doi: 10.4061/2011/246734. Epub 2011 Jun 4. Int J Nephrol. 2011. PMID: 21716690 Free PMC article.
-
Association between the Achievement of Target Range CKD-MBD Markers and Mortality in Prevalent Hemodialysis Patients in Taiwan by Using the Kidney Disease: Improving Global Outcomes Clinical Guidelines.Biomed Res Int. 2016;2016:1523124. doi: 10.1155/2016/1523124. Epub 2016 Nov 27. Biomed Res Int. 2016. PMID: 28003998 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical